Assessment of respiratory muscles and motor function in children with SMA treated by nusinersen
Pediatric Pulmonology2020Vol. 56(1), pp. 299–306
Citations Over TimeTop 10% of 2020 papers
Marta Gómez‐García de la Banda, Alessandro Amaddeo, Sonia Khirani, Sandrine Pruvost, Christine Barnérias, Ivana Dabaj, A. Bénézit, Julien Durigneux, Robert Carlier, Isabelle Desguerre, Susana Quijano‐Roy, Brigitte Fauroux
Abstract
In children with SMA Type 2, respiratory muscle performance was significantly better after six injections of nusinersen as compared with age-matched SMA Type 2 historical controls.
Related Papers
- → Mammalian Models of Spinal Muscular Atrophy(2016)10 cited
- → Pharmacological and clinical profile of Onasemnogene Aveparvovec, the first gene therapy for spinal muscular atrophy (SMA)(2021)3 cited
- → Recent research on the treatment of spinal muscular atrophy.(2022)2 cited
- → Efficacy and safety of nusinersen in children with later-onset spinal muscular atrophy (SMA): results of the phase 3 CHERISH study(2017)1 cited
- → Perspectives on models of spinal muscular atrophy for drug discovery(2004)17 cited